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Protein interacting with C kinase 1 suppresses 
invasion and anchorage-independent growth of 
astrocytic tumor cells
Louisa M. R. Cockbilla,*, Kai Murka,*,†, Seth Loveb, and Jonathan G. Hanleya
aSchool of Biochemistry, University of Bristol, Bristol BS8 1TD, United Kingdom; bSchool of Clinical Sciences, University 
of Bristol, Bristol BS10 5NB, United Kingdom
ABSTRACT Astrocytic tumors are the most common form of primary brain tumor. Astrocytic 
tumor cells infiltrate the surrounding CNS tissue, allowing them to evade removal upon surgi-
cal resection of the primary tumor. Dynamic changes to the actin cytoskeleton are crucial to 
cancer cell invasion, but the specific mechanisms that underlie the particularly invasive phe-
notype of astrocytic tumor cells are unclear. Protein interacting with C kinase 1 (PICK1) is a 
PDZ and BAR domain–containing protein that inhibits actin-related protein 2/3 (Arp2/3)-de-
pendent actin polymerization and is involved in regulating the trafficking of a number of cell-
surface receptors. Here we report that, in contrast to other cancers, PICK1 expression is 
down-regulated in grade IV astrocytic tumor cell lines and also in clinical cases of the disease 
in which grade IV tumors have progressed from lower-grade tumors. Exogenous expression 
of PICK1 in the grade IV astrocytic cell line U251 reduces their capacity for anchorage-inde-
pendent growth, two-dimensional migration, and invasion through a three-dimensional ma-
trix, strongly suggesting that low PICK1 expression plays an important role in astrocytic tu-
morigenesis. We propose that PICK1 negatively regulates neoplastic infiltration of astrocytic 
tumors and that manipulation of PICK1 is an attractive possibility for therapeutic intervention.
INTRODUCTION
Astrocytic tumors are the most common form of primary brain tumor 
in humans (Furnari et al., 2007; Louis et al., 2007). Ninety-five per-
cent of grade IV astrocytic tumors (glioblastomas) are “primary,” oc-
curring de novo. The remaining 5% develop slowly from grade II 
tumors to form “secondary” grade IV tumors (Furnari et al., 2007; 
Louis et al., 2007; Sturm et al., 2014). Patients with grade IV tumors, 
both primary and secondary, have a life expectancy of approxi-
mately 1 yr. Two major characteristics of astrocytic tumors cause 
them to be refractory to current treatments: tumor heterogeneity 
and the highly invasive nature of the neoplastic cells (Giese et al., 
2003; Furnari et al., 2007; Aum et al., 2014). Astrocytic tumor cells 
infiltrate deep into CNS tissue surrounding the primary tumor, allow-
ing them to evade removal upon surgical resection of the primary 
tumor, and a common occurrence postsurgery is for the locally infil-
trating cells to form tumors adjacent to the edge of the resection 
cavity. Astrocytic tumor cells can spread long distances from the 
initial tumor site to form tumors throughout the CNS (Giese et al., 
2003). The mechanisms that underlie the particularly invasive phe-
notype of these cells are unclear.
Dynamic alterations to the actin cytoskeleton are crucial to all 
forms of cancer cell invasion (Nurnberg et al., 2011). Invasion of 
brain tissue by neoplastic astrocytes is initiated by the formation of 
membrane protrusions—lamellipodia and invadopodia (Maestro 
et al., 2001), which are driven by the polymerization of actin fila-
ments that physically push the plasma membrane outward. Focal 
adhesions are formed at the protrusive leading edge to generate 
traction, and retraction of the rear of the cell then occurs through 
actin:myosin contractile forces (Olson et al., 2009). The actin-re-
lated protein (Arp) 2/3 complex is the major nucleator for the po-
lymerization of branched actin networks necessary to drive mem-
brane protrusions and hence cell motility (Welch et al., 1997; 
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somal trafficking and surface expression of 
α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid (AMPA) receptors, which are 
the major excitatory neurotransmitter recep-
tors in the CNS (Xia et al., 1999; Hanley, 
2008). The BAR and PDZ domains, as well as 
the Arp2/3-binding region of PICK1 in the 
C-terminal region, are critical for AMPA re-
ceptor trafficking (Xia et al., 1999; Jin et al., 
2006; Rocca et al., 2008; Nakamura et al., 
2011). PICK1 also interacts with the cyto-
solic domains of plasma membrane proteins 
involved in promoting tumorigenesis, such 
as Eph receptor tyrosine kinases, ephrins, 
Coxsackie-adenovirus receptor (CAR), and 
ErbB2/Her2 (Jaulin-Bastard et al., 2001; Ex-
coffon et al., 2004), suggesting that PICK1 
may play a role in cell motility or growth via 
such interactions. In addition, we recently 
demonstrated that endogenous PICK1 
modulates the morphological plasticity of 
nontransformed astrocytes (Murk et al., 
2013).
Here we report that PICK1 expression is 
reduced in astrocytic tumor cell lines and 
also in tumor tissue from patients with astro-
cytic tumors, particularly those that are high 
grade. We demonstrate that exogenous ex-
pression of PICK1 reduces the ability of as-
trocytic tumor cells to grow in an anchor-
age-independent manner, to migrate, and 
to invade in a three-dimensional (3D) envi-
ronment. We therefore propose that PICK1 
acts as a negative regulator of neoplastic 
infiltration by astrocytic tumors.
RESULTS
PICK1 expression is reduced in human 
astrocytic tumor cell lines
Although deregulation in PICK1 expression 
has been shown in a number of human can-
cers, it has not previously been investigated 
in astrocytic tumors (Zhang et al., 2010). 
Therefore we evaluated PICK1 expression in 
a number of astrocytic tumor cell lines origi-
nating from adult (Figure 1, B and D) and 
pediatric (Figure 1, A and C) tumors of 
grades I–IV. Most of the astrocytic tumor cell 
lines showed a reduction in PICK1 expres-
sion compared with that in the nontumorigenic human astrocyte 
control (Figure 1, A–D). In six of the seven grade IV cell lines, the 
reduction in PICK1 expression was statistically significant (Figure 1, 
C and D), suggesting that an aberration in PICK1 expression is a 
frequent occurrence in astrocytic tumors. The variability in PICK1 
expression across the cell lines is consistent with the highly hetero-
geneous nature of astrocytic tumors (Furnari et al., 2007; Aum et al., 
2014). The more dramatic reduction in PICK1 expression in cells 
derived from grade IV than with grade I tumors was confirmed by 
immunocytochemistry, which showed stronger labeling of PICK1 in 
the grade I Res186 tumor cells than in grade IV U251 (Figure 1E). An 
alternative grade IV line, SNB19, was also analyzed, which showed 
an intermediate level of PICK1 expression (Figure 1, D and E). 
Mullins et al., 1998). A frequent observation in many forms of can-
cer, including astrocytic tumors, is deregulation of Arp2/3-depen-
dent actin dynamics (Kurisu et al., 2010; Liu et al., 2013). Protein 
interacting with C-kinase 1 (PICK1) is a negative regulator of 
Arp2/3-dependent actin polymerization (Rocca et al., 2008), and 
PICK1 expression is up-regulated in a number of different cancers 
(Zhang et al., 2010). Of importance, however, PICK1 has not previ-
ously been studied in astrocytic tumors.
PICK1 is a cytosolic protein composed of a BAR and a PDZ do-
main, which mediate lipid membrane and protein interactions, re-
spectively (Staudinger et al., 1995; Jin et al., 2006). PICK1 has a 
well-documented role in neuronal synaptic plasticity, in which it 
functions as a trafficking protein, particularly in regulating the endo-
FIGURE 1: PICK1 expression is reduced in human astrocytic tumor cell lines. (A–D) Western blot 
analysis of PICK1 protein expression in lysates of astrocytic tumor cell lines compared with 
control human astrocytes (hAstro). (A, C) Pediatric tumor cell lines. (B, D) Adult tumor cell lines. 
(C, D) Quantification of blots after calibration of PICK1 to GAPDH levels and normalization to 
control hAstro value on each blot. Values are mean ± SEM, n = 3. ANOVA p = 0.0001 for C and 
D. *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA with Bonferroni’s post hoc test). 
(E) Res186 (grade I), U251 (grade IV), and SNB19 (grade IV) cell lines were stained for PICK1 
(red) and F-actin (green). Far right, merged images. Scale bar, 10 μm.
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gests that these mutations have no detectable effect on the 
localization of FlagPICK1 in U251 cells (Supplemental Figure S1B). 
Figure 2, C, E, and F, shows that exogenous expression of the 
Arp2/3 mutant but not the BAR and PDZ mutants suppressed U251 
anchorage-independent growth to a level similar to that of WT 
PICK1. These results indicate that both BAR and PDZ domain inter-
actions of PICK1, but not its interaction with Arp2/3, are crucial for 
suppression of U251 anchorage-independent growth.
PICK1 impedes astrocytic tumor cell migration and invasion
Migration and invasion through tissue is another key characteristic of 
cancer cells (Hanahan and Weinberg, 2000), and the invasion of as-
trocytic tumors through the CNS is known to be particularly aggres-
sive (Furnari et al., 2007). To investigate the effect of PICK1 on U251 
cell migration, we used a scratch-wound assay to assess the velocity 
of cell movement from a confluent cell monolayer into the wound 
area. As expected, U251 cells migrated faster than Res186 cells 
(Figure 3, A and B, and Supplemental Movies S1A and S1F). Exog-
enous expression of WT PICK1 caused a significant reduction in the 
migration rate of U251 cells (Figure 3, A and B, and Supplemental 
Movies S1A and S1B). Surprisingly, cells expressing the Arp2/3 mu-
tant migrated at a similar rate to cells expressing exogenous WT 
PICK1, suggesting that the interaction with Arp2/3 is not required 
for the reduction in migration caused by PICK1 (Figure 3, A and C, 
and Supplemental Movie S1C). Cells expressing the BAR mutant 
also migrated at a similar rate, suggesting that BAR domain interac-
tions with phospholipids and actin are also not involved (Figure 3, A 
and C, and Supplemental Movie S1D). In contrast, the suppression 
of cell migration by PICK1 was blocked by the PDZ mutation, indi-
cating that PDZ domain protein–protein interactions of PICK1 are 
critically involved (Figure 3, A and C, and Supplemental Movie S1E). 
We also investigated the migration of another grade IV cell line, 
SNB19. Exogenous expression of WT-PICK1 by lentiviral transduc-
tion caused a small but significant reduction in migration rate of 
these cells (Supplemental Figure S2 and Supplemental Movies S2A 
and S2B; Sturm et al., 2014), providing further evidence that PICK1 
reduces the migration of astrocytic tumor cells.
To analyze actin dynamics in cells at the leading edge of the 
scratch wound, we generated similar lentiviral vectors that ex-
press Lifeact–green fluorescent protein (GFP) instead of mCherry 
and used live imaging to analyze the dynamics of filamentous (F)-
actin structures in real time (Supplemental Movie 2, A and B; 
Louis et al., 2007). The movies demonstrate that exogenous WT 
PICK1 expression did not suppress dynamic alterations in the 
actin cytoskeleton.
Cancer cells invade through a 3D environment, and although 
the process of invasion uses similar actin-based mechanisms to mi-
gration, there are key differences—in particular, the involvement of 
specialized invasive structures (invadopodia; Yamaguchi and 
Condeelis, 2007). To investigate 3D invasion, we used a cell spher-
oid assay to measure invasion of lentivirus-transduced U251 cells 
through Matrigel. As expected, Res186 cell spheroids were not 
able to invade into the Matrigel (Figure 4A). Exogenous expression 
of WT PICK1 dramatically reduced the invasion of cells away from 
the main “tumor-like” cell spheroid (Figure 4, B and C). All three 
PICK1 mutations blocked this effect, revealing that Arp2/3 binding, 
PDZ domain interactions, and BAR domain interactions are re-
quired for the suppressive activity of PICK1 on invasion (Figure 4, B 
and D). These experiments demonstrate that reduced PICK1 ex-
pression in U251 astrocytic tumor cells is a critical part of the mech-
anism that underlies the high level of invasiveness of these cells in 
a 3D environment.
Although PICK1 expression in U251 cells was at the limit of detec-
tion, we observed no differences in subcellular distribution of PICK1 
among the three astrocytic tumor cell lines analyzed.
To investigate the role of reduced PICK1 expression in astrocytic 
tumor biology, we generated lentiviral constructs to exogenously 
increase PICK1 expression in the U251 grade IV cell line. The viral 
vectors bicistronically encode mCherry and PICK1 via an internal ri-
bosome entry site (IRES) or mCherry-IRES alone as a control. Virally 
transduced cells were sorted by fluorescence activated cell sorting 
(FACS) to generate homogeneous populations by analysis of the 
mCherry fluorescence signal. The FACS-sorted cells were gated 
with parameters to select for a relatively low level of mCherry fluo-
rescence and therefore a low level of exogenous PICK1 to avoid 
excessive PICK1 expression (see Supplemental Figure S1 for charac-
terization of exogenous PICK1 expression in virally transduced U251 
cells). We tested these cells in a variety of assays to define the effect 
of altered PICK1 expression on the functional characteristics of 
grade IV tumor cells.
PICK1 reduces astrocytic tumor cell growth in an anchorage- 
independent setting
A defining characteristic of cancer is its limitless and uncontrolled 
proliferative capacity (Hanahan and Weinberg, 2000). Previous work 
suggested that PICK1 may play a role in cancer cell proliferation; for 
example, in cancers in which PICK1 is up-regulated, it is found to act 
as a proliferation-promoting factor (Zhang et al., 2010). We there-
fore investigated the effect of PICK1 on the proliferation of grade IV 
U251 cells. In the exponential phase (when grown in an adherent 
manner), the rate of control (mCherry alone) U251 cell proliferation 
did not differ from cells expressing exogenous wild-type (WT) PICK1 
(Figure 2, A and B). A grade I cell line (Res186) was analyzed for 
comparison and, as expected, had much slower exponential growth 
than both populations of U251 cells (Figure 2, A and B). These re-
sults indicate that PICK1 expression has no effect on the prolifera-
tion of U251 cells when adhered to a solid substratum.
An important feature of cell transformation in high-grade malig-
nant cancers is an ability to sustain anchorage-independent growth 
(Mori et al., 2009). To investigate whether the expression of PICK1 
affects anchorage-independent growth, we monitored the forma-
tion of colonies generated from U251 cells grown in soft agar. Of 
interest, exogenous WT PICK1 expression caused a marked reduc-
tion in colony-forming efficiency (Figure 2, C and D), indicating re-
duced capacity to grow in an anchorage-independent manner. 
However, the colony-forming efficiency of the U251 cells expressing 
exogenous WT PICK1 was greater than that of the grade I cell line 
(Res186), which did not produce any colonies greater than the 
threshold size, indicating that the growth of the grade I cell line is 
exclusively anchorage dependent. This experiment demonstrates 
that low PICK1 expression plays a role in the capacity for anchorage- 
independent growth in astrocytic tumors.
To investigate the mechanism that underlies PICK1 suppression 
of U251 anchorage-independent growth, we generated PICK1 len-
tiviral vectors to express a number of PICK1 mutations that disrupt 
specific intermolecular interactions. These included the C-terminal 
PICK1 interaction with the Arp2/3 complex (W413A), the BAR do-
main interaction with membrane phospholipids and F-actin (KK251, 
252EE), and PDZ domain interactions with various protein binding 
partners (KD27, 28AA; Terashima et al., 2004; Jin et al., 2006; Xu 
and Xia, 2006; Rocca et al., 2008, 2013). These constructs, hereafter 
referred to as Arp2/3 mutant, BAR mutant, and PDZ mutant, respec-
tively, were expressed at comparable levels in U251 cells (Supple-
mental Figure S1, A and B), and immunocytochemical analysis sug-
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activation is deregulated in astrocytic tumors (Jaffe and Hall, 2005; 
Khalil and El-Sibai, 2012). PICK1 interacts with Rac and also with the 
Rac GEF Kalirin7 (Penzes and Jones, 2008; Rocca and Hanley, 2015). 
PICK1 also regulates the trafficking of receptors known to be 
PICK1 increases Rac1 activation in U251 cells
The small GTPase Rac1 plays a critical role in transducing external 
stimuli into intracellular signaling events in a range of cellular 
processes, including growth, migration, and invasion, and Rac1 
FIGURE 2: Exogenous expression of PICK1 reduces the anchorage-independent growth but not anchorage-dependent 
proliferation in a grade IV astrocytic tumor cell line. (A) PICK1 expression had no effect on anchorage-dependent 
proliferation. Fluorescence is proportional to cell number for each well of cells plated in triplicate for each cell line, 
shown as sigmoidal logistic regression curves with four parameters. Values are mean ± SEM, n = 4. (B) Velocity of cell 
proliferation, calculated as slope coefficient in the linear exponential growth phase of each curve. ANOVA p = 0.0011. 
**p < 0.01 (one-way ANOVA with Bonferroni’s post hoc test, compared with Res186). (C) Exogenous PICK1 expression 
reduced anchorage-independent growth. Representative images after 1 wk of growth. Cells were seeded on soft agar 
at a density of 1 × 105 per 6-cm dish. (D) Quantification of experiments shown in C; values are mean percentage 
colony-forming efficiency (CFE) ± SEM, n = 6. Res186 cells never grew colonies larger than threshold size, and so 
Student’s t test was used to compare control and WT-PICK1–expressing cells, **p = 0.0044. (E) BAR and PDZ domain 
interactions were required for PICK1 to reduce anchorage- independent growth. Representative images after 1 wk of 
growth. Cells were seeded on soft agar at a density of 1 × 105 per 6-cm dish. (F) Quantification of experiments shown in 
E. ANOVA p = 0.0016, **p < 0.01 (repeat-measure ANOVA with Bonferroni post hoc test).
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only in the grade II and III astrocytic tumors, with the grade IV astro-
cytic tumors displaying a much wider variance in PICK1 expression 
that was not statistically significant from meningioma.
Review of the clinical and neuropathological findings indicated 
that most of the grade IV tumors were primary glioblastomas (with a 
short clinical history and no mutation in the isocitrate dehydrogenase 
genes IDH1 or IDH2; Agnihotri et al., 2014) rather than secondary 
glioblastomas that had progressed from grade II and III neoplasms. 
The significantly lower PICK1 expression in the grade II and III pro-
gressive tumors and the wide variance in expression in the grade IV 
tumors led us to investigate whether reduced PICK1 expression is a 
specific characteristic of progressive rather than de novo astrocytic 
tumors. Therefore we separately analyzed the cases of progressive 
disease (i.e., all of the grade II and III tumors and a subpopulation of 
the grade IV tumors; Figure 6B). Indeed, PICK1 mRNA expression in 
all of the progressive tumors was significantly lower than that of me-
ningiomas, suggesting that reduced PICK1 expression is particularly 
relevant in progressive forms of astrocytic neoplasia. Figure 6C high-
lights another important feature of PICK1 expression in progressive 
tumors: a reduction in PICK1 expression in five of the six patients who 
had repeat neurosurgical resections of tumor tissue as their disease 
progressed from grade II to grade IV neoplasia. The one patient who 
did not show a reduction in PICK1 with tumor progression was re-
viewed, and the histological findings indicated that this tumor differed 
upstream of Rac signaling, for example, Eph receptors (Torres et al., 
1998). To investigate possible mechanisms for PICK1 regulation of 
invasion, growth, and migration, we examined Rac1 activation using 
GST-PAK pulldowns. Exogenous expression of WT-PICK1 caused a 
marked increase in Rac1 activation compared with controls, which 
was blocked by PDZ, BAR, and Arp2/3 mutations (Figure 5). Be-
cause all three PICK1 mutants were ineffective in increasing Rac1 
activation, these data are consistent with a role for PICK1 in regulat-
ing Rac1 signaling in astrocytic tumor cell invasion, which is similarly 
sensitive to all three mutations (Figure 4, B and D).
Clinical astrocytic tumor tissue displays a reduction in PICK1 
expression
Our in vitro data demonstrate that PICK1 suppresses anchorage-in-
dependent growth, migration, and invasion in U251 cells, indicating 
that PICK1 acts as a suppressor of infiltration in astrocytic tumors. To 
evaluate how these in vitro observations relate to the human dis-
ease, we analyzed the expression of PICK1 in surgically resected tu-
mor specimens by use of quantitative PCR (qPCR) to quantify PICK1 
mRNA. In keeping with our in vitro findings, the tumors had an over-
all reduction in PICK1 mRNA compared with that in meningioma, 
which have a relatively noninvasive phenotype (Figure 6A; Louis 
et al., 2007; Alahmadi and Croul, 2011). However, post hoc testing 
showed the reduction in PICK1 mRNA expression to be significant 
FIGURE 3: Exogenous expression of PICK1 reduces the migration speed of U251 cells in a scratch-wound assay. 
(A) Representative phase contrast images of grade I Res186 (nontransduced) and grade IV U251 cells transduced with 
control (empty vector), WT-PICK1, or mutant PICK1 lentivirus, 0 and 16 h after scratching. (B, C) Cell velocity 
(micrometers/minute) was assessed by tracking individual cell trajectories every 20 min for 16 h. The box plots show the 
interquartile range, with mean and whiskers from the 10th to the 90th percentile, n = 5. (B) Res186 cells were compared 
with both control (empty vector) and WT-PICK1 U251 cells, ANOVA p < 0.0001 with Bonferroni post hoc tests also 
comparing control to WT PICK1, *p < 0.05, ***p < 0.001. (C) PICK1 mutants compared with WT PICK1, ANOVA 
p = 0.0293, *p < 0.05 (one-way ANOVA with Bonferroni post hoc tests).
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been examined in astrocytic tumors (Zhang 
et al., 2010), and here we show a reduction 
in PICK1 expression in both astrocytic tumor 
cell lines and human clinical samples. Using 
functional in vitro assays, we show that the 
exogenous expression of WT PICK1 in as-
trocytic tumor cells reduces anchorage-in-
dependent colony growth, two-dimensional 
(2D) migration, and invasion in a 3D 
environment.
A significant reduction in PICK1 expres-
sion compared with control astrocytes was 
shown for the majority but not all of the as-
trocytic tumor cell lines. A notable excep-
tion was the highly invasive grade IV U87 
cell line. There is a precedent for distinct 
U87 expression profiles compared with 
other invasive cell lines. For example, high 
levels of ephrinB3 are found in U251 cells, 
and ephrin B3 knockdown reduces cell mi-
gration. In contrast, U87 cells have low eph-
rinB3 expression, and overexpression 
causes an increase in cell migration (Nakada 
et al., 2006). Therefore the experimental 
data from both cell lines support a role for 
ephrin B3 in increasing cell migration but 
suggest that the invasive phenotype in U87 
involves an ephrinB3-independent mecha-
nism. This observation, together with our 
data for PICK1, is consistent with the hetero-
geneous nature of astrocytic tumors.
The 2D migration assays demonstrate 
that exogenous expression of WT PICK1 re-
duces the migration rate of U251 and 
SNB19 cells into a scratch wound, indicating 
that the low PICK1 expression observed in 
these cells contributes to their migratory po-
tential. By selective mutagenesis, we 
showed that the PICK1 PDZ domain is es-
sential for this effect on 2D migration. PICK1 
PDZ domain interacts with numerous cell 
surface proteins to regulate their trafficking 
through the endosomal system and also 
with cytosolic signaling proteins such as pro-
tein kinase C (PKC) and calcineurin (Xu and 
Xia, 2006). We propose that the highly mo-
tile and invasive phenotype of U251 cells is 
caused, at least in part, by a deficit in PICK1-
mediated trafficking of or signaling through 
as-yet-unidentified proteins (Madsen et al., 
2005). For example, PICK1 interacts with several members of the 
Eph receptor tyrosine kinase family, as well as with their ephrin li-
gands (Torres et al., 1998). Eph receptor–ephrin interactions are in-
volved in sensing cell-to-cell contacts (Son et al., 2014), and initiate 
downstream signaling events that, via Rho GTPases, regulate actin 
dynamics in both the healthy state (Puschmann and Turnley, 2010; 
Batson et al., 2013) and numerous cancers, including astrocytic 
tumors (Nakada et al., 2006; Astin et al., 2010; Pasquale, 2010). 
Consistent with this hypothesis, we find that exogenous expression 
of PICK1 increases Rac1 activation. Although Rac1 is typically found 
to promote astrocytic tumor progression (Fortin Ensign et al., 2013), 
reduced levels of Rac1 have also been reported to correlate with an 
from the other progressive tumors in being predominantly gemisto-
cytic at the time of initial presentation (Supplemental Figure S3).
These data demonstrate that PICK1 expression is significantly 
reduced in astrocytic tumors, particularly those that have progressed 
from low to high grade. This reflects our in vitro data and suggests 
that the increase in invasive behavior that accompanies malignant 
progression of astrocytic tumors may result, at least in part, from a 
reduction in PICK1 expression.
DISCUSSION
Our results demonstrate a role for PICK1 in regulating astrocytic tu-
mor cell growth and invasion. PICK1 expression had not previously 
FIGURE 4: Exogenous expression of PICK1 reduces the ability of U251 cells to invade in a 3D 
environment. (A, B) Representative images of spheroids generated from Res186 (nontransduced) 
and U251 cells transduced with control (empty vector) and PICK1 lentiviruses and placed in 
Matrigel. Images were taken on the day the spheroids were placed in Matrigel (day 0) and again 
on day 5. (C, D) Mean area of spheroid invasion ± SEM, n = 6. (C) WT-PICK1 compared with 
control, **p = 0.009 (t test). (D) PICK1 mutants compared with WT PICK1, ANOVA p = 0.0007, 
*p < 0.05, ***p < 0.001 (one-way ANOVA with Bonferroni post hoc tests).
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invasive phenotype, and increased activation of Rac1 can cause a 
reduction in astrocytic tumor invasion (Khalil and El-Sibai, 2012; 
Reyes et al., 2013). These latter studies are consistent with our re-
sults, since the high Rac1 activity found in the WT PICK1–expressing 
cells correlates with reduced tumorigenic characteristics.
In the scratch-wound experiments using Lifeact-GFP, dynamic F-
actin was clearly visible in leading-edge filopodia and lamellipodia 
polarized toward the scratch wound. Although lamellipodia forma-
tion and dynamics are Arp2/3 dependent (Machesky et al., 1997; 
Mullins et al., 1998), increasing PICK1 expression appeared to have 
little effect on these structures. This is consistent with our observa-
tion that the interaction with Arp2/3 is not involved in PICK1-depen-
dent inhibition of migration of U251 cells.
We also found that exogenous expression of PICK1 suppressed 
the invasion of U251 cells through a 3D matrix. This is further evi-
dence that the low PICK1 expression level in these cells is at least 
partly responsible for their highly invasive phenotype. In contrast to 
2D migration, however, in which only the PDZ mutation disrupted 
PICK1 function in the suppression of motility, all three mutations 
tested prevented exogenous PICK1 from suppressing the capacity 
of the U251 cells for 3D invasion. This demonstrates that interac-
tions with PDZ domain ligands, the Arp2/3 complex, and phospho-
lipid membranes are all necessary for this aspect of PICK1 function. 
These results indicating PICK1 manipulation of the actin cytoskele-
ton and trafficking via the BAR domain as necessary in 3D invasion 
but not 2D migration are consistent with the greater mechanistic 
complexity of 3D invasion than 2D migration (Olson and Sahai, 
2009; Ridley, 2011). Moreover, previous evidence suggested that 
Arp2/3 inhibition is more effective in suppressing invasion than mi-
gration of U251 cells (Liu et al., 2013). This is consistent with our re-
sults, which suggest that a requirement for Arp2/3 inhibition by 
PICK1 is important for invasion but not for migration.
Although exogenous expression of WT 
PICK1 repressed the growth of anchorage-
independent colonies, it did not alter the 
proliferation rate of U251 cells when ad-
hered to a solid substratum. This indicates 
that the repressive effect of WT PICK1 on 
growth/proliferation depends on cell adhe-
sion, suggesting that the mechanism by 
which WT PICK1 affects proliferation is indi-
rect, through adhesive complex signaling. 
This hypothesis is supported by our results 
showing that the PDZ domain and the BAR 
domain, important for PICK1-mediated traf-
ficking of cell surface receptors such as 
those important in adhesive interactions, 
are crucial for suppression of anchorage-in-
dependent colony growth by PICK1. Further 
support for this concept comes from the 
previous observation that the PICK1 PDZ 
domain interacts with plasma membrane 
adhesive proteins such as CAR, which plays 
an important role in astrocytic tumor growth 
(Kim et al., 2003; Excoffon et al., 2004).
Our results show that PICK1 PDZ domain 
interactions are essential for all aspects of 
U251 cell behavior tested. Further work will 
be necessary to identify PICK1-interacting 
proteins that show aberrant activity or local-
ization in astrocytic tumor cells as a result of 
insufficient PICK1 to regulate relevant 
FIGURE 5: Exogenous expression of PICK1 WT in U251 cells 
increases levels of active Rac1. Lysates of U251 cells transduced with 
control (empty vector), and PICK1 lentiviruses were incubated with 
GST-PAK CRIB domain (PAK) immobilized on glutathione-agarose 
beads to isolate GTP-bound Rac1. Lysates from control cells were also 
incubated with GST alone as a negative control (Ctrl). Representative 
Western blots show the levels of active (PAK-bound) and total (input) 
Rac1. Tubulin was also analyzed as a loading control. Graph shows 
levels of active Rac1 normalized to the inputs and to tubulin; n = 5, 
ANOVA p = 0.0449, with Bonferroni post hoc tests, *p < 0.05.
FIGURE 6: PICK1 mRNA expression is reduced in clinical samples of human astrocytic tumors.  
(A, B) Vertical scatter plots of the relative levels of PICK1 mRNA in human astrocytic tumor tissue 
compared with the control group, a cohort of relatively noninvasive grade I meningiomas. The 
geometric mean and 95% confidence interval are shown for each tumor set (log 2 scale) ± SEM. 
(A) Entire cohort of excised astrocytic tumors, ANOVA p = 0.0058. (B) Only the progressive tumors 
from the cohort, ANOVA p = 0.0078. *p < 0.05, **p < 0.01 (Kruskal–Wallis test with Dunn’s post 
hoc tests). (C) Relative PICK1 mRNA expression of progressive tumors from six patients. Change 
in PICK1 expression accompanying the progression from grade II to grade IV in each patient.
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Kingdom), A172 and U251 (kindly provided by Wilfried Roth, Ger-
man Cancer Research Center, Heidelberg, Germany), 1321N1 (a 
generous gift from Amal Shervington, University of Lancashire, Pres-
ton, United Kingdom), and human astrocytes (normal human astro-
cytes, referred to here as hAstro; Lonza, Basel, Switzerland) were 
maintained in DMEM supplemented with 10% fetal bovine serum 
(FBS), glutamine, and penicillin/streptomycin (P/S) at 37°C, 4% CO2.
Antibodies and reagents
For immunoblotting, we used anti-PICK1 (Neuromab; University of 
California, Davis, Davis, CA), glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH; Abcam, Cambridge, UK), Rac1 (BD Biosci-
ences, San Jose, CA), tubulin (Sigma-Aldrich, Dorset, UK), and 
horseradish peroxidase–conjugated secondary antibodies (Sigma-
Aldrich). Immunoreactive bands were detected by enhanced che-
miluminescence. For immunofluorescence microscopy, we used 
anti-PICK1 (Abcam), anti-Flag (Sigma-Aldrich), and cy3-conjugated 
secondary antibody (Jackson ImmunoResearch Labs, West Grove, 
PA). F-actin was visualized with Alexa 647–conjugated phalloidin 
(Invitrogen, Paisley, UK).
Lentiviral constructs
mCherry IRES empty and mCherry IRES PICK1 cassettes were li-
gated into a pCDF vector (Systems Biosciences, Mountain View, 
CA). Mutagenesis was carried out by PCR to generate Arp2/3-bind-
ing (W413A), BAR (KK251, 252EE), and PDZ (KD27, 28AA) muta-
tions (Terashima et al., 2004; Jin et al., 2006; Rocca et al., 2008, 
2013).
Proliferation assay
The adherent cell growth assays were carried out using the CyQuant 
NF cell proliferation assay kit (Life Technologies, Paisley, UK) accord-
ing to the manufacturer’s instructions (Liu et al., 2007). Fluorescence 
readout (proportional to cell number) was measured every day for 
7 d on the Fluoroskan Ascent FL (ThermoScientific, Paisley, UK), ex-
citing at 485 nm and detecting at 538 nm. Four-parameter sigmoi-
dal logistic regression curves were fitted to the 7-d fluorescence 
readout from which the velocity of cell growth during the exponen-
tial linear phase of growth was calculated.
Anchorage-independent assay
This was carried out as previously described (Rutka et al., 1994; 
Chell et al., 2006). Cells were grown suspended in medium-enriched 
agar, and colonies that were of threshold size or above (threshold 
determined with reference to a central graticule in the viewing field) 
were counted 1 wk after seeding. The colony-forming efficiency 
(CFE) was then calculated for each cell line. The surface area of one 
field of view was 15.89 mm2, and the surface area of each dish was 
2826 mm2. Therefore there were 177.84 possible fields of view that 
could be counted from. The percentage CFE was calculated in Excel 
(Microsoft) according to the equation
%CFE
177.84 Average number of colonies per field of view





This was performed as previously described (Engelhard et al., 2001). 
Cells were grown until confluent on glass-bottomed microwell dishes 
(MatTek, Ashland, MA), after which medium was exchanged for CO2-
independent medium (Leibovitz’s L-15 Life Technologies], 10% FBS, 
and P/S) containing 125 μM cytosine β-d-arabinofuranoside (Sigma-
Aldrich) and then scratched with a p200 pipette tip. Images were 
acquired from multiple sites every 20 min for 16 h. Individual cells 
signaling pathways or trafficking events. The additional requirement 
for Arp2/3 binding in 3D invasion and BAR domain interactions in 
both invasion and anchorage-independent growth raises the possi-
bility that these processes involve trafficking of distinct plasma mem-
brane proteins with different requirements for PICK1 molecular inter-
actions. Alternatively, additional PICK1-mediated mechanisms may 
be involved, such as regulation of actin-based structural dynamics.
The analysis of PICK1 expression in clinical samples of human 
astrocytic tumors showed that a reduction in PICK1 is a relevant 
phenotypic feature of the human disease. This was particularly evi-
dent in progressive tumors, with a reduction in PICK1 expression as 
the tumors progressed from grade II to IV. Our in vitro data suggest 
that this further reduction in PICK1 expression is likely to be biologi-
cally important in increasing invasiveness. Up-regulating PICK1 or 
stimulating its downstream effectors may offer a means of prevent-
ing this. Overall the primary grade IV tumors in our study did not 
show a significant reduction in PICK1; expression was low in some 
cases but high in others, reflecting the heterogeneity of this group. 
It seems likely that multiple molecular pathways may lead to the in-
vasive behavior of tumor cells in primary glioblastomas, in which 
case, PICK1 manipulation would be a therapeutic option in only a 
subset of these tumors.
Our choice of U251 cells for the majority of our functional experi-
ments was based on our initial observation that these cells have a 
consistently low level of PICK1 expression. They are therefore a 
good model system for investigating the importance of PICK1 in 
migration and invasion of astrocytic tumors. Our data from clinical 
samples indicate that this is most relevant to progressive rather than 
de novo tumors. Unfortunately, insufficient information is available 
to confirm such an origin of U251 cells.
The marked reduction in PICK1 expression in both the astrocytic 
tumor cell lines and human cases of the disease suggests that PICK1 
acts as a tumor suppressor in this type of tumor. This is in contrast to 
previous reports of PICK1 up-regulation and purported oncogenic 
activity in other types of cancer (Zhang et al., 2010). This cancer 
type–specific deregulation of PICK1 is most likely due to the differ-
ences in the properties of the cells of origin and of the tumors them-
selves. Astrocytes have an inherent ability to move through CNS 
tissue (Barres, 2008), unlike epithelial cells. In contrast, even the 
highest-grade astrocytic tumors rarely enter the bloodstream and 
disseminate hematogenously, as many cancers do (Giese et al., 
2003; Furnari et al., 2007). These distinctive characteristics of astro-
cytes and astrocytic tumor cells might explain why a protein that is 
involved in regulating invasion in one type of tumor might not play 
the same role in others. It might also be relevant that basal PICK1 
expression is higher in the brain than in most other tissues 
(Staudinger et al., 1995), suggesting that PICK1 has functions that 
are specific to the CNS.
Further investigation is needed to elucidate the pathways re-
sponsible for down-regulation of PICK1 in astrocytic tumors and 
determine the molecular processes through which it influences the 
migration, invasion, and anchorage-independent growth of astro-
cytic tumors. The relevance of PICK1 suppression in at least a subset 
of the disease in humans makes manipulation of PICK1 an attractive 
possibility for therapeutic intervention in this notoriously aggressive 
and difficult-to-treat disease.
MATERIALS AND METHODS 
Cell culture
Human astrocytic tumor cell lines KNS42, LN229, Res186, Res259, 
SF268, SNB19, U87, U118, U138, U251, and UW479 (a generous 
gift from Chris Jones, Institute of Cancer Research, London, United 
4560 | L. M. R. Cockbill, K. Murk, et al. Molecular Biology of the Cell
use of the comparative cycle threshold (CT) method with a PCR cy-
cling profile of 95°C for 20 s with 40 cycles of 95°C for 1 s and 60°C 
for 20 s. The CT was set at 0.2, and PICK1 astrocytic tumor transcript 
levels were calculated relative to TBP and PICK1 expression in the 
control group by means of the Livak 2−ΔΔCt method (Livak and 
Schmittgen, 2001). Because it was not possible to obtain normal, 
nonneoplastic astrocytic tissue from the human patients, we used 
tissue from five WHO grade I meningiomas as an arbitrary compara-
tor, selected because low-grade meningiomas are relatively nonin-
vasive tumors (Louis et al., 2007).
Statistics
Analyses were performed using two-tailed t tests or one-way analy-
sis of variance (ANOVA) for parametric data and the Kruskal–Wallis 
test for nonparametric data, with the Bonferroni or Dunn test for 
post hoc pairwise comparisons.
were traced, and the velocity of cell movement was calculated. The 
same migration assay was performed with cells expressing Lifeact-
GFP imaged 2.5 h after scratching, with images taken every 30 s for 
a further 2.5 h.
Cell spheroid invasion assay
Spheroids were prepared by the hanging-drop method, adapted 
from a previous report (Del Duca et al., 2004), by suspending a small 
volume of cells on an inverted plate lid above wells containing 5 ml of 
DMEM. After 7 d, the spheroids were maneuvered onto glass-bot-
tomed microwell dishes, and Matrigel (BD Biosciences) was prepared 
at 1:1 dilution with DMEM (without phenol red; Life Technologies) 
and added on top of the spheroids. Fluorescence and phase contrast 
images of the spheroids were acquired on days 0 and 5 by confocal 
microscopy. Spheroid invasion was calculated using ImageJ (National 
Institutes of Health, Bethesda, MD) as the area from the edge of the 
spheroid bulk to the most peripheral invasive extensions.
PAK Rac1 activation assay
Glutathione S-transferase (GST)–PAK or GST alone was immobi-
lized on glutathione-agarose beads (Sigma-Aldrich). Beads were 
washed and incubated with 1.5–5 mg of lysate prepared from vi-
rally transduced U251 cells for 1 h at 4°C with rotation. Beads were 
washed four times, and then the bound fraction was eluted with 
SDS sample buffer. Proteins were separated by SDS–PAGE and de-
tected by Western blotting with antibodies against Rac1 and tubu-
lin. For each condition, the GST-PAK–bound signal was normalized 
to input and to tubulin loading controls. For each experiment, Rac1 
activity of the PICK1 WT and mutant conditions was normalized to 
the control.
Clinical samples and histology
Frozen human tumor tissue was obtained from the diagnostic ar-
chive in the Department of Neuropathology, North Bristol NHS Trust 
(Bristol, United Kingdom) with approval by the National Research 
Ethics Service Committee South West (REC ref 11/H0107/2). This 
tissue had been removed during neurosurgical treatment of patients 
with astrocytic tumors. The tumors had all been subjected to de-
tailed histological assessment and classified and graded according 
to World Health Organization (WHO) criteria (Louis et al., 2007). 
Samples of unfixed tumor tissue from the biopsies had been stored 
at −80°C. For this study, we used small samples (<1 mg) of the fro-
zen tumor tissue. We analyzed 50 astrocytic and five meningioma 
tumor tissue samples.
Clinical sample preparation
The tissue was homogenized and lysed in TRIzol reagent (Life Tech-
nologies) according to the manufacturer’s instructions. The Ribo-
green RNA Assay kit (Molecular Probes Quan-iT; Life Technologies) 
was used to quantify RNA extract according to the manufacturer’s 
instructions, with fluorescence measured in a FLUOstar OPTIMA 
reader (BMG Labtech, Aylesbury, UK). The high-capacity cDNA re-
verse transcriptase kit (Applied Biosystems, Life Technologies) was 
used to reverse transcribe the RNA, and the resulting cDNA was 
quantified using the Picogreen cDNA assay kit.
qPCR
We performed qPCR using TaqMan Assay on Demand (AOD) Primer 
and Probe combination kits (Life Technologies) Hs00202661_m1 for 
PICK1 and Hs00427620_m1 for the calibrator, Tata box–binding 
protein (TBP). The qPCR measurements were performed according 
to manufacturer’s instructions on the Applied Biosystems ViiA 7 by 
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